Alkermes (NASDAQ:ALKS) Issues FY 2025 Earnings Guidance

Alkermes (NASDAQ:ALKS) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.030-1.210 for the period, compared to the consensus EPS estimate of 1.740. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Alkermes Trading Up 2.9 %

Alkermes stock traded up $0.96 during midday trading on Thursday, reaching $34.46. The stock had a trading volume of 418,971 shares, compared to its average volume of 1,573,937. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. The firm has a market cap of $5.57 billion, a price-to-earnings ratio of 17.67, a price-to-earnings-growth ratio of 1.83 and a beta of 0.49. Alkermes has a 52-week low of $22.90 and a 52-week high of $34.33. The company has a fifty day moving average of $30.21 and a 200 day moving average of $28.68.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.11. Alkermes had a return on equity of 24.92% and a net margin of 22.15%. On average, analysts anticipate that Alkermes will post 2.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Piper Sandler reissued an “overweight” rating and set a $37.00 target price (down from $38.00) on shares of Alkermes in a research note on Friday, October 25th. Deutsche Bank Aktiengesellschaft started coverage on shares of Alkermes in a research report on Tuesday. They issued a “buy” rating and a $40.00 price objective for the company. Mizuho raised their target price on shares of Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. The Goldman Sachs Group lowered their price target on Alkermes from $32.00 to $30.00 and set a “buy” rating for the company in a report on Friday, October 25th. Finally, Cantor Fitzgerald decreased their target price on Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Alkermes currently has a consensus rating of “Moderate Buy” and an average target price of $37.08.

Insider Transactions at Alkermes

In other news, SVP Christian Todd Nichols sold 5,208 shares of the stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $29.15, for a total value of $151,813.20. Following the sale, the senior vice president now owns 60,703 shares in the company, valued at $1,769,492.45. This represents a 7.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Craig C. Hopkinson sold 100,918 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $32.05, for a total transaction of $3,234,421.90. Following the transaction, the executive vice president now owns 44,290 shares of the company’s stock, valued at $1,419,494.50. This represents a 69.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 179,189 shares of company stock valued at $5,723,518 in the last quarter. 4.89% of the stock is currently owned by corporate insiders.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.